Prescribing overview
ProZinc is veterinary U-40 insulin; canine and feline initiation schedules differ.
Key prescribing checks
- Hypoglycemia is a major insulin risk; do not administer during a hypoglycemic episode. Weakness, altered behavior, collapse or seizures require prompt assessment.
- Confirm food intake, vomiting, glucose monitoring and the owner’s written sick-day instructions before administration.
- Diet, body weight, concurrent illness and other medicines can change insulin needs. Switching insulin or changing frequency requires close monitoring and a prescriber’s specific plan; canine and feline instructions differ.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs and cats
US FDA-approved ProZincDiabetes mellitus: reduce hyperglycemia and associated signs
Not an emergency ketoacidosis stabilization regimen.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Insulin supplies glucose-lowering hormone activity.
Absorption, distribution, metabolism and elimination
Canine label studies show variable, nonlinear relationships between dose, insulin exposure and glucose response.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
ProZinc
Subcutaneous U-40 injectable suspension; Dogs, Cats
Contraindications · when not to use
- Hypersensitivity to the insulin or any product ingredient; current hypoglycemia.
Precautions & monitoring
- Severe ketoacidosis or an anorectic, lethargic or vomiting patient requires stabilization; monitor glucose closely. Safety in young, breeding, pregnant or lactating animals has not been evaluated.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Hypoglycemia can cause seizures, coma or death; injection-site reactions occur.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| CatsDiabetes mellitusProZinc U-40 suspension | Initial 0.2–0.7 IU/kg Subcutaneous · Every 12 hours Initial regimen only; veterinary reassessment required | Give with or immediately after a meal; use U-40 syringes. Verify full dosing label ↗ |
| DogsDiabetes mellitusProZinc U-40 suspension | Initial 0.5–1.0 IU/kg Subcutaneous · Once daily Initial regimen only; veterinary reassessment required | Insulin-naive dogs start at lower end; give with or immediately after a meal. Verify full dosing label ↗ |
Not a patient-specific prescription. Veterinarian alone titrates dose/frequency using clinical response and glucose curves; never automatically convert insulin.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
ProZinc
Subcutaneous U-40 injectable suspension; Dogs, Cats
- Glucocorticoids and progestogens antagonize insulin; label advises avoiding them.
Monitoring
Track glucose, appetite, weight, water intake and hypoglycemia; establish sick-day instructions.
Client counseling
Gently roll, never shake; do not use persistent clumps. Seek urgent help for weakness, collapse or seizures.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Refrigerate upright at 2–8°C; protect from light; never freeze. Discard 10-mL vials after 60 days, 20-mL after 80 days from first puncture.
Brands, formulations & ingredient identity
Active ingredients
Protamine zinc recombinant human insulin
Other searchable names: Protamine zinc insulin · PZI
ProZinc is protamine zinc recombinant human insulin. The phrase human insulin describes the molecule; the cited product itself is veterinary-labeled for dogs and cats.
ProZinc is a U-40 suspension and requires a U-40 syringe. Other insulin concentrations or insulin types are not interchangeable from a generic-name search.
The label directs gentle rolling rather than shaking. Persistent clumps or visible particles after mixing are a reason not to use the vial and to contact the veterinarian.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
ProZinc
- Formulation
- Subcutaneous U-40 injectable suspension
- Label / product scope
- Dogs · Cats
Veterinary insulin; syringe concentration must match the U-40 product.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →